LobbyingThe University of Texas MD Anderson Cancer Center lobbying by quarter
The University of Texas MD Anderson Cancer Center's latest lobbying report covers Q2 2026, at $80K. The four quarters Q4 2025–Q3 2026 total $260K. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Medicare/Medicaid.
The University of Texas MD Anderson Cancer Center
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $260K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $75K | 1 |
| Q1 2023 | $75K | 1 |
| Q2 2023 | $75K | 1 |
| Q3 2023 | $75K | 1 |
| Q4 2023 | $75K | 1 |
| Q1 2024 | $80K | 1 |
| Q2 2024 | $70K | 1 |
| Q3 2024 | $70K | 1 |
| Q4 2024 | $80K | 1 |
| Q1 2025 | $90K | 1 |
| Q2 2025 | $190K | 1 |
| Q3 2025 | $100K | 1 |
| Q4 2025 | $100K | 1 |
| Q1 2026 | $80K | 1 |
| Q2 2026 | $80K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$328.8K · 15 reports
- Medicare and Medicaid$328.8K · 15 reports
- Government issues$183.3K · 6 reports
- Law enforcement and criminal justice$93.8K · 7 reports
- Medical research and clinical labs$90K · 4 reports
- Education$65.8K · 5 reports
- Immigration$65.8K · 5 reports
- Health issues$62.5K · 4 reports
- Science and technology$54.7K · 3 reports
- Pharmacy$41.3K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Health & Human Services, Dept of (HHS)8 reports
- Food & Drug Administration (FDA)4 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseThe University of Texas MD Anderson Cancer Center | $1.3M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $80K |
| 05/08for Q1 | In-house | $80K |
| 05/08for Q1 2025 | In-house | $90K |
| 05/04for Q1 | In-house | $800K |
| 01/26for Q4 2025 | In-house | $100K |
| 25/10/23for Q3 2025 | In-house | $100K |
| 25/07/22for Q2 2025 | In-house | $190K |
| 25/05/01for Q1 2025 | In-house | $900K |
| 25/01/23for Q4 2024 | In-house | $80K |
| 24/10/22for Q3 2024 | In-house | $70K |
| 24/07/21for Q2 2024 | In-house | $70K |
| 24/04/22for Q1 2024 | In-house | $80K |
| 24/01/21for Q4 2023 | In-house | $75K |
| 24/01/21for Q4 2023 | In-house | $75K |
| 23/10/19for Q3 2023 | In-house | $75K |
| 23/07/20for Q2 2023 | In-house | $75K |
| 23/04/20for Q1 2023 | In-house | $75K |
| 23/01/20for Q4 2022 | In-house | $75K |